A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer
- Authors
- Song, Hong Suk; Do, Young Rok; Chang, Heung Moon; Ryu, Min Hee; Lee, Kyung Hee; Kim, Yeul Hong; Hong, Dae Sik; Cho, Jae Yong; Lee, Kyoung Eun; Kim, Si Young
- Issue Date
- 10월-2008
- Publisher
- SPRINGER
- Keywords
- pancreatic cancer; capecitabine; gemcitabine; chemotherapy
- Citation
- CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.62, no.5, pp.763 - 768
- Indexed
- SCIE
SCOPUS
- Journal Title
- CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Volume
- 62
- Number
- 5
- Start Page
- 763
- End Page
- 768
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/122621
- DOI
- 10.1007/s00280-007-0661-y
- ISSN
- 0344-5704
- Abstract
- Purpose This open-label, multicenter phase II study was conducted to investigate the efficacy and safety of capecitabine plus gemcitabine combination chemotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Patients and methods We enrolled 63 patients who received capecitabine 830 mg/m(2) orally twice daily on days 1-21 plus gemcitabine 1000 mg/m(2) as a 30-min infusion on days 1, 8 and 15 every 4 weeks for up to six cycles. Results A total of 14 patients had partial responses giving an overall response rate of 22% (95% confidence interval [CI] 13-34%) in the intent-to-treat population. The median time to progression and overall survival were 3.9 months (95% CI 3.5-5.7) and 7.5 months (95% CI 5.0-10.0), respectively, and 1-year survival rate was 27.1% in the intent-to-treat population. Capecitabine plus gemcitabine was well tolerated. Grade 3 hematological adverse events were neutropenia (21%) and thrombocytopenia (2%); the only grade 4 hematological events were anemia (2%) and neutropenia (6%). Non-hematological adverse events were mainly gastrointestinal events and hand-foot syndrome, which affected 16% of patients. Grade 3/4 non-hematological events were infrequent. Conclusion The combination of capecitabine plus gemcitabine appears to be active and well tolerated as first-line treatment in patients with advanced/metastatic pancreatic cancer.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.